Aug 05, 2025
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025
Jun 09, 2025
Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada
May 22, 2025
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology
May 14, 2025
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase
Mar 13, 2025
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024
Mar 12, 2025
Lipocine Announces FDA Labeling Changes for Testosterone Products
Feb 06, 2025
Lipocine Receives Updated Regulatory Guidance on LPCN 1154
Dec 17, 2024
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
Nov 18, 2024
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session
Oct 31, 2024
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea
Oct 10, 2024
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
Oct 02, 2024
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
Sep 05, 2024
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
Jun 25, 2024
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
Jun 10, 2024
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024
May 09, 2024
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
May 08, 2024
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
May 01, 2024
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
Apr 11, 2024
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
Mar 28, 2024
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis